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Objectives: The objectives of our large observational study were to describe the prevalence of 
cardiac and noncardiac comorbidities in a community-based population of patients hospitalized 
with acute myocardial infarction (AMI) at all medical centers in central Massachusetts, and to 
examine whether multiple comorbidities were associated with in-hospital death rates and 
hospital length of stay. 
Methods: The study sample consisted of 2,972 patients hospitalized with AMI at all eleven 
greater Worcester medical centers in central Massachusetts during the three study years of 
2003, 2005, and 2007. 
Results: The average age of this hospitalized population was 71 years, 55% were men, 93% 
were Caucasian, and approximately one third had developed an ST segment elevation AMI 
during the years under study. Hypertension (75%) was the most common cardiac condition 
identified in patients hospitalized with AMI whereas renal disease (22%) was the most common 
noncardiac comorbidity diagnosed in this study population. Approximately one in every four 
hospitalized patients had any four or more of the seven cardiac conditions examined, while one 
in 13 had any three or more of the five noncardiac conditions studied. Patients with four or more 
cardiac comorbidities were more than twice as likely to have died during hospitalization and 
have a prolonged hospital length of stay, compared to those without any cardiac comorbidities. 
Patients with three or more noncardiac comorbidities had markedly increased odds of dying dur-
ing hospitalization and having a prolonged hospital stay compared to those with no noncardiac 
comorbidities previously diagnosed.
Conclusion: Our findings highlight the need for additional contemporary data to improve 
the short-term outcomes of patients hospitalized with AMI and multiple concurrent medical 
illnesses.
Keywords: population-based study, chronic conditions, acute coronary syndrome
Introduction
More than 140 million Americans have one or more chronic conditions.1 The number 
of Americans living with multiple chronic conditions will continue to increase as 
the population ages and fewer patients die from acute manifestations of cardiac and 
noncardiac conditions.2–4 In general, and among patients with cardiovascular disease, 
the presence of multiple comorbidities has been associated with increased mortality, 
greater utilization of health care resources, and larger health care expenditures.5,6
Coronary heart disease (CHD) is the leading cause of death in Americans and is 
associated with a high burden of comorbidities that play an important role in disease 
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progression and response to treatment.7–9 Although multiple 
cardiac comorbidities have been associated with adverse 
post-discharge survival rates in patients hospitalized with 
acute myocardial infarction (AMI),10 important in-hospital 
events, including mortality, length of stay, and use of differ-
ent treatment approaches, have not been extensively studied 
in patients with AMI according to the presence of multiple 
cardiac or noncardiac comorbidities.11 The relative lack of 
data on the magnitude and impact of multiple comorbidities 
may limit our ability to further improve the targeting of 
evidence-based therapeutics, thereby improving the outcomes 
of patients hospitalized with AMI.
The primary objective of our study was to describe the 
prevalence of cardiac and noncardiac comorbidities in a 
community-based population of patients hospitalized at all 
medical centers in central Massachusetts with AMI in 2003, 
2005, and 2007. A secondary study objective was to examine 
whether the presence of multiple cardiac and noncardiac 
comorbidities was associated with the use of various treat-
ment approaches, in-hospital mortality, and hospital length 
of stay in patients hospitalized with AMI during the years 
under study. Data from the population-based Worcester Heart 
Attack Study were utilized for this investigation.12–14
Methods
The Worcester Heart Attack Study is an ongoing population-
based investigation examining long-term trends in the 
incidence, hospital, and post discharge case-fatality rates of 
AMI in residents of the Worcester, MA, metropolitan area 
hospitalized at all greater Worcester medical centers on an 
approximate biennial basis between 1975 and 2007.12–14 In 
brief, computerized printouts of patients discharged from all 
greater Worcester hospitals with possible AMI  (International 
Classification of Disease, Ninth Revision: [ICD 9] codes: 
410–414, 786.5) were identified. Cases of possible AMI were 
independently validated using predefined criteria for AMI. 
These criteria included a suggestive clinical history, serum 
enzyme level elevations in excess of the normal range at 
each participating hospital, and serial electrocardiographic 
findings during hospitalization consistent with the presence 
of AMI. Patients who satisfied at least two of these three 
criteria, and were residents of the Worcester metropolitan 
area, were included.12–14
The present study population consisted of adult men 
and women of all ages who were hospitalized with AMI in 
2003, 2005, and 2007 at any of eleven medical centers in 
the Worcester metropolitan area. As mentioned previously, 
we carry out surveillance of this population on a biennial, 
not an annual, basis. We restricted our study sample to this 
relatively recent period because of the availability of data on 
several important measures of cardiac and noncardiac comor-
bidity and to provide relatively contemporary insights into 
the prevalence and impact of various comorbidities in this 
patient population. This observational study was approved 
by the Office for the Protection of Human Subjects in 
Research and Institutional Review Board at the University 
of Massachusetts Medical School.
Data collection
Trained nurses and physicians abstracted information on 
patients’ demographic characteristics, medical history, 
clinical data, and treatment practices through the review 
of hospital medical records of patients with independently 
confirmed AMI. These factors included patients’ history of 
previously diagnosed comorbidities and AMI order (initial 
versus prior) and type (ST-elevation myocardial infarction 
[STEMI] versus non-ST-elevation myocardial infarction 
[NSTEMI]).15,16 Data on treatment practices during hospi-
talization included the prescribing of six effective cardiac 
medications (angiotensin converting inhibitors/angiotensin 
receptor blockers, anticoagulants, lipid lowering agents, 
beta blockers, aspirin, and thrombolytics) and two coronary 
interventional procedures (coronary artery bypass grafting 
[CABG], and percutaneous coronary intervention [PCI]). 
The main outcomes of interest were in-hospital case-fatality 
rates (CFRs) and hospital length of stay.
Comorbid conditions that had been previously diagnosed 
in this patient population were categorized into cardiac 
and noncardiac comorbidities. For purposes of the present 
analysis we considered seven cardiac comorbidities, includ-
ing atrial fibrillation, CHD (prior angina pectoris, CHD, 
myocardial infarction [MI], CABG, or PCI), diabetes, heart 
failure, hypertension, peripheral vascular disease, and stroke. 
The five noncardiac comorbidities that we examined included 
anemia, depression, cancer, chronic obstructive pulmonary 
disease (COPD), and chronic kidney disease (CKD). We 
selected and categorized these cardiac and noncardiac 
comorbidities based on a review of the prior literature, their 
established associations with either the development of, or 
prognosis after, AMI, and their relative frequency in this 
patient population.10,17,18
Data analysis
We estimated the overall prevalence of individual comor-
bidities and multiple cardiac and noncardiac comor-
bidities in this patient population. We further categorized 
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cardiac comorbidities (0, 1, 2, 3, and $4), and noncardiac 
comorbidities (0, 1, 2, and $3) according to the number 
of comorbid conditions previously diagnosed based on the 
review of information contained in hospital medical records. 
Differences in patient demographic and clinical character-
istics, cardiac medications and interventional procedures 
received, and hospital CFRs and length of stay (LOS) 
according to number of cardiac or noncardiac comorbid 
conditions were examined using the Analysis of Variance 
test for continuous variables and the chi-square test for 
categorical variables.
Multivariable logistic regression analyses were performed 
to examine the association between number of cardiac and 
noncardiac comorbid conditions and our principal study out-
comes of in-hospital mortality (dead versus alive) and LOS 
(.3 versus #3 days), while adjusting for several potential 
confounding variables. These variables included patient age, 
sex, race (white versus non-white), marital status, year of 
hospitalization (2003, 2005, or 2007), and AMI order and 
type. Sequentially, we began our multivariable adjustment 
including only cardiac or only noncardiac comorbidities in 
separate models. We then placed these cardiac and noncardiac 
factors in a model concurrently to examine associations with 
our principal hospital outcomes. Multivariable adjusted odds 
ratios (OR) and 95% confidence intervals (CI) for the risk of 
dying during hospitalization or having a prolonged hospital 
stay according to the number of cardiac and noncardiac 
comorbidities present were calculated in a standard man-
ner. In addition, we examined the relations between various 
combinations (ie, co-occurrence of specific conditions) of 
multiple cardiac or noncardiac comorbidities and hospital 
CFRs and LOS.
Results
Patient characteristics
The study sample consisted of 2,972 residents of the 
Worcester metropolitan area hospitalized with independently 
validated AMI at all greater Worcester medical centers dur-
ing 2003, 2005, and 2007. The average age of this patient 
population was 70.8 years, 55.1% were men, and most were 
white (92.5%). About one-third of patients presented with 
a STEMI (31.6%), almost two-thirds had not experienced 
a prior AMI (64.5%), and 9.7% died during their acute 
hospitalization.
In examining differences in selected demographic and 
clinical characteristics in relation to number of diagnosed 
cardiac or noncardiac comorbidities (Table 1), patients with 
multiple cardiac or noncardiac conditions were significantly T
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Cardiac condition
Noncardiac condition
Anemia
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Atrial fibrillation
CHD
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Heart failure
Hypertension
PVD
Stroke
0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0
14.6
55.4
34.8
25.3
74.9
19.3
11.8
14.3
15.3
21.7
18.2
18.2
%
Figure 1 Prevalence of cardiac and noncardiac comorbidities.
Abbreviations: ChD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease.
more likely to be older, female, unmarried, have a history 
of prior MI, and present with a NSTEMI. These patients 
were also more likely to have presented with higher serum 
glucose levels, but lower estimated glomerular filtration 
rate (eGFR) and serum cholesterol levels, at the time of 
hospital admission than patients with fewer or no comorbid 
conditions.
Prevalence of previously diagnosed 
cardiac and noncardiac comorbidities
Among all comorbid conditions previously diagnosed at 
the time of their hospitalization for AMI, hypertension 
(74.9%) was the cardiac condition most commonly identi-
fied, whereas chronic kidney disease (21.7%) was the most 
common noncardiac comorbidity diagnosed in this patient 
population (Figure 1).
In our study population, 12.9% of patients had none of 
the cardiac comorbidities examined, 19.8% had any one, 
24.2% had any two, 18.7% had any three, and 24.6% had 
any four or more of the cardiac conditions examined. In 
terms of noncardiac comorbidities, 44.8% of patients had 
none, 32.0% had any one, 15.6% had any two, and 7.6% had 
any three or more of the noncardiac conditions examined. 
Among all patients, 9.6% had neither of the cardiac nor the 
noncardiac comorbidities studied, while 4.3% had $4 cardiac 
and $3 noncardiac comorbidities.
receipt of cardiac medications  
and interventional procedures  
and prior comorbidities
On average, patients received 4.2 of the six cardiac medica-
tions (angiotensin converting inhibitors/angiotensin receptor 
blockers, anticoagulants, lipid lowering agents, beta blockers, 
aspirin, and thrombolytics) examined during their acute index 
hospitalization; 79.1% of patients received at least four of these 
effective cardiac medications.
Each of these cardiac medications, with the exception of 
thrombolytics, was prescribed to three-quarters or more of 
patients hospitalized with AMI (Table 2). After multivariable 
adjustment, patients with two noncardiac (OR = 0.72, 95% 
CI = 0.53, 0.97) or three or more noncardiac (OR = 0.62, 
95% CI = 0.42, 0.92) comorbidities were significantly less 
likely to have received at least four of the effective cardiac 
medications, compared with patients without any previously 
diagnosed noncardiac comorbidity; however, no significant 
differences in treatment practices were found according to 
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the number of cardiac comorbidities previously diagnosed 
in this population.
Nearly one-half of patients underwent a PCI and 5.5% 
underwent CABG surgery during their index hospitalization. 
Patients were considerably less likely to have undergone a 
PCI with increasing cardiac and noncardiac comorbidity 
burden (Table 2). After multivariable adjustment, patients 
with four or more cardiac comorbidities (OR = 0.59, 95% 
CI = 0.41, 0.86) or patients with one noncardiac (OR = 0.67, 
95% CI = 0.55, 0.82), two noncardiac (OR = 0.52, 95% 
CI = 0.40, 0.69), or three or more noncardiac comorbidities 
(OR = 0.35, 95% CI = 0.23, 0.52) were significantly less 
likely to have undergone a PCI, compared with patients 
without any previously diagnosed cardiac or noncardiac 
comorbidity; however, no significant associations were 
observed between the likelihood of undergoing CABG sur-
gery according to the number of comorbidities present at the 
time of hospitalization for AMI.
hospital death rates and length  
of stay and prior comorbidities
Having multiple cardiac or noncardiac comorbidities was 
significantly associated with higher hospital CFRs and longer 
LOS. There was a dose-response relationship between number 
of cardiac or noncardiac comorbidities and in-hospital death 
rates and LOS (Table 3, P for trend ,0.001). The hospital 
CFR increased from 3.7% to 14.2% as the number of cardiac 
comorbidities increased from zero to four or more conditions; 
similarly, the hospital CFR increased from 6.9% to 15.9% 
as the number of noncardiac comorbidities increased from 
zero to three or more conditions.  Approximately two-thirds 
of patients with four or more cardiac comorbidities had a 
LOS .3 days, compared with 39.8% of patients without 
any cardiac comorbidity. Similarly, 70.7% of patients with 
three or more noncardiac comorbidities had a LOS .3 days 
compared to 47.8% of patients without any noncardiac 
comorbidity (Table 3).
In multivariable logistic regression models adjusting 
for the number of cardiac and noncardiac comorbidities 
concurrently, patients with any two, three, or four or more 
cardiac comorbidities were two to three times as likely to 
have died during hospitalization, compared with those with 
no cardiac comorbidities (Table 4). Patients with two non-
cardiac (OR = 1.63, 95% CI = 1.12, 2.37), or three or more 
noncardiac comorbidities (OR = 1.76, 95% CI = 1.11, 2.78) 
were also more likely to have died during hospitalization 
compared with those without any noncardiac comorbidities. 
In addition, we found that patients with any two, three, or T
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four or more cardiac comorbidities were at increased odds 
of a prolonged hospital LOS (.3 days) compared with those 
with no cardiac comorbidities (Table 4). Patients with any 
one, two, or three or more noncardiac comorbidities were 
also significantly more likely to have a prolonged hospital 
course compared with those without any noncardiac comor-
bidities (Table 4).
We further examined the association between multiple 
coexisting conditions and in-hospital mortality and LOS. 
Due to the limited number of patients with certain comor-
bidity combinations, we focused on the three most common 
combinations of previously diagnosed comorbid conditions. 
The most frequent combination of two or more cardiac 
comorbidities was “CHD + hypertension” (n = 340, 11.4%) 
followed by “CHD + diabetes + hypertension” (n = 182, 
6.1%) and “ diabetes + hypertension” (n = 156, 5.3%). Among 
patients with these multiple comorbid conditions, 8.2%, T
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Table 4 Multivariable adjusted association† between frequency 
of noncardiac and cardiac comorbidities and hospital case-fatality 
(CF) and length of stay*
Variable OR (95% CI) OR (95% CI) OR (95% CI)#
Hospital CF
Cardiac comorbidity
 0 1.00 1.00
 1 1.36 (0.69, 2.67) 1.31 (0.67, 2.57)
 2 2.13 (1.12, 4.04) 2.00 (1.05, 3.82)
 3 2.34 (1.20, 4.57) 2.14 (1.10, 4.20)
 $4 3.35 (1.73, 6.48) 2.80 (1.43, 5.49)
noncardiac comorbidity
 0 1.00 1.00
 1 1.30 (0.94, 1.80) 1.20 (0.86, 1.67)
 2 1.86 (1.29, 2.69) 1.63 (1.12, 2.37)
 $3 2.12 (1.36, 3.31) 1.76 (1.11, 2.78)
Variable OR (95% CI) OR (95% CI) OR (95% CI)
Length of stay (.3 days)
Cardiac comorbidity
 0 1.00 1.00
 1 1.20 (0.90, 1.60) 1.16 (0.87, 1.55)
 2 1.43 (1.07, 1.92) 1.36 (1.01, 1.83)
 3 1.81 (1.31, 2.50) 1.65 (1.19, 2.29)
 $4 2.42 (1.74, 3.37) 2.03 (1.45, 2.86)
noncardiac comorbidity
 0 1.00 1.00
 1 1.32 (1.10, 1.59) 1.24 (1.03, 1.50)
 2 1.84 (1.44, 2.36) 1.64 (1.27, 2.11)
 $3 2.04 (1.46, 2.85) 1.73 (1.23, 2.44)
Notes: *adjusted for age, sex, race, marital status, year of hospitalization, and aMi 
order and type; #adjusted for age, sex, race, marital status, year of hospitalization, 
aMi order and type, and the noncardiac and cardiac morbidities examined; †the Ors 
for the first two table columns refer to the multivariable adjusted estimates when 
the cardiac comorbidities and noncardiac comorbidities are respectively analyzed 
separately, whereas the third column presents the adjusted estimates when both the 
cardiac and noncardiac comorbidities are included together in the model.
Abbreviations: AMI, acute myocardial infarction; CF, case-fatality; CI, confidence 
interval; Or, odds ratio.
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7.7%, and 9.6% of these patients, respectively, died during 
hospitalization (all were not significantly different than the 
overall hospital death rate of 9.8%), and 53.7%, 62.6%, and 
55.1% had a LOS .3 days, respectively (all were not signifi-
cantly different than the overall frequency of 56.1%).
Among those with two or more noncardiac conditions, 
the most frequent combination was “anemia + CKD” 
(n = 104, 3.5%), followed by “COPD + CKD” (n = 59, 2.0%), 
and “COPD + depression” (n = 54, 1.8%). Among these 
patients, 14.4%, 11.9%, and 14.8%, respectively, died during 
hospitalization (all were not significantly different than the 
overall hospital death rate of 9.8%), while 76.9%, 69.5%, and 
70.4% had a LOS .3 days, respectively (all were significantly 
[P , 0.05] higher than the overall frequency of 56.1%).
Discussion
The results of this population-based observational study dem-
onstrated that patients with multiple cardiac or noncardiac 
comorbidities had a higher odds of dying during hospital-
ization for AMI and having a more prolonged hospital stay 
compared to those with fewer or no previously diagnosed 
cardiac or noncardiac conditions. Patients with multiple 
cardiac or noncardiac comorbidities were significantly less 
likely to have undergone a PCI than patients with fewer 
comorbid conditions, but there were no significant differences 
in medication treatment practices according to the number 
of cardiac comorbidities present.
Prevalence of cardiac  
and noncardiac comorbidities
In our study population, the vast majority (87%) had at least 
one cardiac comorbid condition, whereas slightly more than 
half (55%) had at least one noncardiac comorbid condition 
previously diagnosed. More than one-half of patients had a 
history of CHD or hypertension, and approximately one-fifth 
had CKD. Among the seven cardiac comorbid conditions 
examined, hypertension was highly prevalent, irrespective of 
the number of cardiac comorbidities previously diagnosed, 
whereas CHD and diabetes were highly prevalent among 
patients with two or more cardiac comorbidities. Similarly, 
among the five noncardiac comorbidities examined, CKD 
was the most prevalent condition whereas anemia was 
more prevalent among patients with two or more cardiac 
comorbidities.
Our findings share similar patterns to the results of a 
recent analysis from the Worcester Heart Attack Study that 
examined trends in the frequency of multiple cardiovascu-
lar comorbidities among patients hospitalized with AMI 
between 1990 and 2007.10 In that analysis, we showed that 
hypertension and diabetes were the two most prevalent 
conditions among these patients.10 The present results are 
also consistent with the findings from other contemporary 
investigations that have studied patients hospitalized with 
AMI, including a community-based study from Kaiser 
Permanente Northern California that demonstrated a high 
burden of hypertension, diabetes, and CHD in this large 
regional population.19 Since the burden of comorbid diseases 
is associated with an increased risk of adverse outcomes, it is 
important to recognize the frequency and importance of these 
common comorbidities and take them into consideration in 
examining differences in treatment practices and outcomes 
in patients hospitalized with AMI.
Factors associated with multiple 
comorbidities
In a prior analysis of data from the Worcester Heart Attack 
Study we found that older individuals, women, nonwhite, 
and widowed patients were more likely to have multiple car-
diovascular comorbidities previously diagnosed than respec-
tive comparison groups.10 In the present study, we extend 
these findings by showing that similar patient demographic 
characteristics were associated with multiple cardiac and 
noncardiac comorbid conditions. In addition, we found that 
patients with multiple cardiac or noncardiac comorbidities 
were more likely to have developed a NSTEMI, have had a 
prior MI, and have higher serum glucose, but lower eGFR 
and serum cholesterol levels, at the time of hospital admis-
sion compared to those without any cardiac or noncardiac 
comorbidities.
hospital treatment practices
Characterizing the magnitude and profile of cardiac and 
noncardiac conditions in patients hospitalized with AMI 
may help explain differences in acute treatment practices and 
inform the design of clinical guidelines and disease manage-
ment practices that are beneficial to these complex and often 
frail patients. The American College of Cardiology/American 
Heart Association guidelines for the use of cardiac medica-
tions in patients hospitalized with AMI have recommended 
the utilization of β-blockers and aspirin (1990), angiotensin-
converting-enzyme (ACE) inhibitors (1996), and the use of 
lipid lowering medications in the 2002 and 2004 guidelines 
for the management of patients with NSTEMI and STEMI, 
respectively.20–23 In the present study, beta blockers and aspi-
rin were prescribed to the majority of hospitalized patients 
whereas thrombolytic agents were rarely prescribed; each of 
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the other medications was prescribed to at least three quarters 
of hospitalized patients.
We observed the frequent use of guideline-directed 
 medications in the treatment of patients hospitalized with 
AMI, irrespective of the number of cardiac comorbid condi-
tions present. This finding may be due, in part, to a ceiling 
effect since these cardiac medications were commonly pre-
scribed to all patients hospitalized with AMI. However, our 
analysis focused on the receipt of cardiac medications during 
hospitalization for AMI in patients with different cardiac and 
noncardiac comorbidities, such as hypertension, diabetes, 
and CKD, which may have been differentially prescribed 
to these patient subgroups in the outpatient setting. Further 
studies should be carried out examining the number and 
type of medications prescribed for outpatients with single 
and multiple chronic comorbidities over the course of their 
long-term follow-up visits.
Since patients with multiple comorbidities tend to be 
older and sicker,10 we observed that patients were less likely 
to have undergone coronary revascularization procedures 
as the frequency of cardiac or noncardiac comorbidities 
increased. Our results suggest that patients with multiple 
comorbidities have a considerably different clinical presenta-
tion than those with fewer comorbid conditions, which may 
make them less likely to receive evidence-based therapies 
at the time of hospital admission and, by extension, increase 
their risk of adverse outcomes. Our results, in combina-
tion with prior study findings, emphasize the importance 
of developing clinical management guidelines specifically 
tailored for hospitalized AMI patients with multiple cardiac 
or noncardiac comorbidities given their high risk of adverse 
outcomes.
Hospital outcomes
There are few published studies describing the relation 
between multiple comorbidities and short- and long-term 
outcomes among patients hospitalized with AMI. A recent 
analysis of data from the Worcester Heart Attack Study 
found that, among patients hospitalized with AMI between 
1990 and 2007, those who had two or more cardiovascular 
comorbidities were at higher risk for dying within 30 days 
and at 1 year after hospital admission compared to patients 
with no comorbid cardiovascular condition.10 A recent analy-
sis of nearly 4,000 patients hospitalized with AMI from the 
PREMIER-QI study at 19 US hospitals between 2003 and 
2004 found that the presence of at least one acute noncardiac 
condition was associated with a markedly increased risk of 
dying during hospitalization.24
In the current study, we observed a dose-response 
relationship between number of cardiac or noncardiac 
comorbidities and in-hospital mortality and prolonged LOS. 
Since clinical guidelines and disease management programs 
typically focus on single conditions, and clinical research 
often excludes persons with multiple chronic conditions, our 
observation that patients with multiple cardiac or noncardiac 
comorbidities were significantly more likely to have experi-
enced adverse hospital outcomes suggests that current clinical 
guidelines need to take into consideration the comparatively 
poorer short-term outlook of these high-risk patients. The 
lack of currently available evidence about the inpatient man-
agement of patients with multiple comorbidities reinforces 
the development of contemporary treatment approaches to 
improve the in-hospital and longer-term outcomes of these 
high-risk patients.
Study strength and limitations
The strengths of the present study include its community-
based design, its large sample of patients hospitalized with 
AMI, and its relatively contemporary perspective in exam-
ining clinically relevant outcomes and hospital treatment 
practices according to the frequency of a number of important 
cardiac and noncardiac comorbidities. Several limitations 
need to be acknowledged, however, in the interpretation of the 
present findings. First, since our study population included 
only patients who had been hospitalized in the Worcester 
metropolitan area, one needs to be careful to extrapolate 
our findings to those who died before hospitalization or 
to those who reside in other geographic areas. Second, 
since the majority of our study participants were white, the 
generalizability of our findings to other race/ethnic groups 
may be limited. Lastly, there is the potential for unmeasured 
confounding as we did not have information available on 
several patient-associated characteristics, such as income, 
education, and psychological factors, that may have affected 
several of the endpoints examined.25
Conclusion
In this study of nearly 3,000 patients hospitalized with AMI 
in central Massachusetts, we observed a high frequency of 
multiple cardiac and noncardiac comorbidities. Presence 
of multiple comorbidities was associated with a higher 
likelihood of dying during hospitalization and being hos-
pitalized for a more prolonged period. Given the aging US 
population, the comorbidity burden in patients with acute 
coronary disease will likely continue to increase. Our find-
ings highlight the need for further contemporary data to help 
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guide the  development of effective treatment modalities for 
the comprehensive management of patients with AMI and 
multiple concurrent medical illnesses with the long-term 
goals of improving the prognosis and quality of life of these 
individuals.
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